Get the Daily Brief
Latest Biotech News
Solve nets $120M to refine ADC linkers – Merck among backers
Solve Therapeutics closed a $120 million financing to advance its antibody‑drug conjugate (ADC) platform focused on novel linkers aimed at improving therapeutic index and stability. The company,...
Stem cells restore primate forelimb function: major step for spinal repair
Two Nature Biotechnology papers report that transplantation of human embryonic stem cell‑derived spinal cord neural stem cells (H9‑scNSCs) restored forelimb function in rhesus monkeys with spinal...
Pig kidney survives 61 days — multi‑omics map immune rejection
Researchers published two Nature papers detailing a 61‑day survival of a genetically modified pig kidney transplanted into a brain‑dead human recipient. The studies provided a multiomics and...
Foli‑seq: fecal exfoliome sequencing enables noninvasive IBD monitoring
Researchers introduced exfoliome sequencing (Foli‑seq), a targeted amplicon approach to profile host mRNA from exfoliated gut cells in feces. The method—validated in Nature Biotechnology—captures...
Roche’s Axelios 1 shows speed and concordance in cancer genomics trials
Roche presented early data on its Axelios 1 sequencing‑by‑expansion (SBX) nanopore platform at the AMP meeting, showing high concordance with Illumina NovaSeq in tumor‑normal whole‑genome...
Merck to buy Cidara for $9.2B – adds Phase III long‑acting flu antiviral
Merck agreed to acquire Cidara Therapeutics for approximately $9.2 billion to add CD388, a Phase III long‑acting influenza antiviral, to its portfolio. The deal follows positive Phase IIb NAVIGATE...
J&J pays $3.05B for Halda... gains RIPTAC prostate program
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash to secure Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915 for...
Stem cell grafts restore monkey hand function – milestone for spinal repair
Two Nature Biotechnology papers report that transplanting human embryonic stem cell–derived spinal cord neural stem cells restored forelimb and hand function in rhesus monkeys with spinal cord...
61‑day pig kidney study maps immune rejection – a xenotransplantation 'encyclopedia'
Researchers published a multiomics investigation of a pig kidney transplanted into a brain‑dead human subject and monitored for 61 days. The work provides an integrated atlas of physiological and...
Nuvalent’s ALK drug posts responses – FDA talks loom vs Pfizer’s Lorbrena
Nuvalent reported Phase 1/2 data for neladalkib in ALK‑positive lung cancer showing tumor shrinkage in a meaningful subset of heavily pretreated patients and durable responses at 12–18 months in...
Solve raises $120M to advance ADCs – linkers aim to fix historical limits
Solve Therapeutics closed a $120 million financing round to advance two antibody‑drug conjugates and scale its novel linker chemistry. The startup, founded by members of the former VelosBio team...
Sofinnova sews up €650M fund — more capital for early therapeutics
Sofinnova Partners closed Capital XI at €650 million (about US$750 million), exceeding its target to back early‑stage biopharma and medtech companies. The firm said the fund will lengthen its...
Foli‑seq captures host RNA in feces — a new noninvasive gut immune readout
Researchers introduced exfoliome sequencing (Foli‑seq), a method that profiles host mRNA from exfoliated eukaryotic cells in feces to monitor intestinal and immune function. The technique yields...
WHO prequalifies BD Onclarity HPV test – expands screening in low‑resource settings
The World Health Organization granted prequalification to Becton Dickinson’s Onclarity HPV assay for use on BD Cor and BD Viper LT molecular platforms, clearing the test for procurement in low‑...
Korro stock collapses after RNA‑editing miss — restructures to extend runway
Korro Bio’s shares plunged about 81% after Phase I/IIa REWRITE data for KRRO‑110 failed to reach projected alpha‑1 antitrypsin (AAT) thresholds. The company reported insufficient functional M‑AAT...
Merck to buy Cidara for $9.2B — Adds long‑acting influenza antiviral
Merck agreed to acquire Cidara Therapeutics for about $9.2 billion to add CD388, a long‑acting neuraminidase inhibitor–Fc conjugate, to its antiviral portfolio. Cidara’s Phase IIb NAVIGATE results...
Nuvalent posts ALK response rates — Eyes fast FDA filing
Nuvalent reported Phase 1/2 data for neladalkib showing tumor shrinkage in a significant subset of ALK‑positive lung cancer patients whose disease progressed after prior ALK inhibitors. The...
Stem cell transplant restores primate hand function — Major translational step
Researchers published in Nature Biotechnology that transplanting human embryonic stem cell–derived spinal cord neural stem cells (H9‑scNSCs) restored forelimb function in rhesus monkeys with...
CRISPR edit of NRF2: reverses chemotherapy resistance in lung cancer
Scientists at ChristianaCare’s Gene Editing Institute reported a CRISPR‑based approach that targets NRF2 to overcome chemotherapy resistance in lung cancer models. The lead sentence of the study...
Solve pulls $120M — Moves two ADCs toward clinic
Solve Therapeutics raised $120 million to advance two antibody‑drug conjugates (ADCs), and the company said the financing will support ongoing preclinical and early clinical development. Backed by...